The final NICE guidance recommends the use of mifamurtide (Mepact, Takeda) in combination with postoperative multi agent chemotherapy as an option for treating high grade resectable non metastatic osteosarcoma (bone cancer) in children, adolescents and young adults, when it's made available at a reduced cost to the NHS under a patient access scheme.

The guidance includes additional recommendations supporting further research into the size of the effect of mifamurtide when combined with the type of chemotherapy typically used in UK clinical practice, as well as further collection of quality of life data from people who are cured.